Solazyme, Inc. (NASDAQ:SZYM), a renewable oil and ingredients company,
is pleased to announce that the US Food and Drug Administration (FDA)
has issued a favorable response to Solazyme’s notification which
concludes that high-oleic algae oil is Generally Recognized as Safe
(GRAS) as an ingredient in food products under the intended conditions
of use.
This No Questions letter will further pave the way for mainstream
adoption of superior quality oleic algae oil with unprecedented
functional, performance and nutritional benefits, enabling the creation
of new products that meet consumer demand for healthy, sustainable
ingredients.
Solazyme’s portfolio of high oleic algae oils are unique in that they
can offer an unprecedented amount of healthy monounsaturated fat
(omega-9s), and 0g trans fat with exceptional stability and low levels
of saturated fat. They have a very light color and neutral flavor
allowing the flavor of foods to come through in recipes. Solazyme’s High
Stability High Oleic algae oil received the prestigious 2014 Innovation
Award from the Institute of Food Technologists.
“We’re committed to delivering innovative ingredients that are better
for both people and the planet. Our algae oils offer more favorable fat
profiles than olive oil, and higher smoke points than canola, helping
customers respond to the growing demand for great tasting and nutritious
food,” said Mark Brooks, SVP, Solazyme Food Ingredients.
Solazyme has also received FDA No Questions letters for the whole food
ingredient products currently offered within the AlgaVia™ portfolio,
including Whole Algal Protein and Whole Algal Flour.
Whole Algal Protein is a vegan-friendly, gluten-free product that
contains a rich collection of protein with fiber, lipids and
micronutrients such as lutein and zeaxanthin. With a protein that is
protected by a natural cell wall, this ingredient enables fortification
in challenging applications such as low pH beverages, dressings and
crackers.
Whole Algal Flour is a trans-fat- and cholesterol-free lipid powder that
enables the creation of healthier products with satisfying taste and
texture. This new fat source enables the reduction or replacement of
dairy fats, oil and egg yolks.
About Solazyme, Inc.
Solazyme, Inc. (Nasdaq:SZYM) is
a leading microalgae innovator that delivers first-of-a-kind,
high-performance oils and ingredients that are better for people and
better for the planet. Starting with microalgae, the world’s original
oil producer, Solazyme creates new, sustainable, high-performance
products. These include renewable oils and powerhouse ingredients that
serve as the foundation for healthier foods; better home, personal care
and industrial products; and more sustainable fuels. Headquartered
in South San Francisco, Solazyme’s mission is to solve some of the
world’s biggest problems with one of its smallest and most ancient life
forms: microalgae.
Forward-Looking Statements
This press release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
about Solazyme, including statements that involve risks and
uncertainties concerning: its commercialization and production plans;
meeting commercialization and technology targets; market acceptance of
its products; and Solazyme’s ability to maintain its relationships with
its partners. When used in this press release, the words “will”, “can”,
“anticipate”, “intends” and other similar expressions and any other
statements that are not historical facts are intended to identify those
assertions as forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any such statement may
be influenced by a variety of factors, many of which are beyond the
control of Solazyme, that could cause actual outcomes and results to be
materially different from those projected, described, expressed or
implied in this press release due to a number of risks and
uncertainties. Potential risks and uncertainties include, among others:
Solazyme’s limited operating history; its limited history in
commercializing products; implementation risk in deploying new
technologies; its limited experience in constructing, ramping up and
operating commercial manufacturing facilities; its ability to sell its
products at a profit; delays related to start-up and ramp-up of
production facilities; its ability to manage operational costs at
production facilities; its ability to enter into and maintain strategic
collaborations; successful product trials by its customers and market
acceptance of its products by end-users; its ability to obtain requisite
regulatory approvals; and its access, on favorable terms, to any
required financing. Accordingly, no assurances can be given that any of
the events anticipated by the forward-looking statements will transpire
or occur, or if any of them do so, what impact they will have on the
results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files
with the Securities and Exchange Commission, including its Quarterly
Report on Form 10-Q, as updated from time to time, for a discussion of
these and other risks. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date of this
press release. Solazyme is not under any duty to update any of the
information in this press release.
Copyright Business Wire 2015